Addex Therapeutics
ADXN
3 hedge funds and large institutions have $13.6K invested in Addex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
31% less capital invested
Capital invested by funds: $19.7K → $13.6K (-$6.17K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$891 |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$312 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
ADAR1 Capital Management
Austin,
Texas
| $9.77K | +$891 | +100 | +11% |
|
|
2
Morgan Stanley
New York
| $3.45K | -$10.2K | -1,147 | -76% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $337 | +$312 | +35 | New |
|
ADXN Hedge Fund Activity: Q3 2024 in Review
3 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2024, worth a combined $13.6K — down 31% from $19.7K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ADXN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $891. The largest seller was Morgan Stanley, cutting an estimated $10.2K.
- 3 institutional investors held Addex Therapeutics (ADXN) as of Q3 2024, up from 2 in Q2 2024.
- Funds reported $13.6K of Addex Therapeutics stock for Q3 2024, down 31% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest Addex Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $891 added.
- The largest Addex Therapeutics seller in Q3 2024 was Morgan Stanley, an estimated $10.2K sold.
Based on aggregated 13F filings for Q3 2024.